(RTTNews) – Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating macular edema due to retinal vein occlusion (RVO). This includes patients with centra
Source link
PS Raj Steels IPO : The Initial Public offering opened for subscription on 12 February…
The production of BrahMos NG (Next Generation), the supersonic missile system, which is at an…
The Indian stock market continued its downward trajectory for the sixth consecutive session on February…
Plus, UniCredit’s bid for Commerzbank finds support within Germany’s industrial base and Lazard’s quick windfall…
SoftBank Group Corp. swung to losses for the December quarter due to a drop in…
Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects her favourite stories…